BRIEF—Immunocore appoints former AstraZeneca exec as CEO

UK-based T Cell Receptor (TCR) biotech firm Immunocore today announced that Bahija Jallal has been appointed as chief executive and director of the board.

With more than 25 years of international leadership experience within the pharmaceutical industry, Ms Jallal joins Immunocore from Anglo-Swedish pharma major AstraZeneca, where she is president of MedImmune, its global biologics research and development arm, and a member of the senior executive team reporting to the CEO.

Sir John Bell, chairman of Immunocore, said: “Bahija is the ideal candidate to lead Immunocore at this transformational point in its development. A champion for science and diversity, Bahija is a highly seasoned pharmaceutical executive with considerable experience in biologics R&D and immuno-oncology. Her appointment will significantly strengthen Immunocore as we advance our lead candidate, IMCgp100, towards commercialization, and our growing pipeline of TCR candidates through clinical development. I would like to extend my thanks also to Andrew Hotchkiss, who has been a highly capable interim CEO of Immunocore, for his support.”